FDA Approves Groundbreaking Pill for Postpartum Depression Treatment

The FDA has approved the first pill, Zurzuvae, specifically designed to treat severe depression after childbirth. Postpartum depression affects thousands of new mothers in the U.S. each year, and while standard treatments like counseling or antidepressants may not work for everyone, Zurzuvae has shown promising results in clinical trials. The pill, taken once a day for 14 days, has been found to reduce signs of depression within a few days for many patients. The drug's milder side effects and oral administration make it a beneficial option for women experiencing extreme postpartum depression.